Results 191 to 200 of about 28,054 (245)

Adaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbations [PDF]

, 2016
et al,, Urano, Fumihiko
core   +1 more source

TEM-based Study of the Phenotype of Astrocytes Differentiated from Induced Pluripotent Stem Cells from a Healthy Donor and a Patient with Parkinson's Disease. [PDF]

Sovrem Tekhnologii Med
Kutukova KA, Ivanov MV, Novosadova EV, Brydun AV, Arsenyeva EL, Novosadova LV, Kokorev IV, Grivennikov IA, Sukhorukov VS, Illarioshkin SN.   +9 more
europepmc   +1 more source

Extracellular Vesicle-Mediated Delivery of Constrained Peptides Disrupts the Pathogenic Interaction of LRRK2-FADD in Parkinson's Disease. [PDF]

J Extracell Biol
Zheng Y, Jurgielewicz BJ, Helton LG, Rideout HJ, Kennedy EJ, Stice SL, Yao Y.   +6 more
europepmc   +1 more source

Genetic evidence for a functional association between Parkinson's disease proteins leucine-rich repeat kinase 2 and α-synuclein during axonal transport. [PDF]

Front Mol Neurosci
Chakraborty P, Bajgain P, Huang J, Islam R, Banerjee R, Gunawardena S.   +5 more
europepmc   +1 more source

LRRK2 kinase activity restricts NRF2-dependent mitochondrial protection in microglia. [PDF]

J Immunol
Weindel CG, Coleman AK, Ellzey LM, Kumar S, Chaisson SL, Davis JR, Patrick KL, Watson RO.   +7 more
europepmc   +1 more source

Carriers of LRRK2 pathogenic variants show a milder, anatomically distinct brain signature of Parkinson's disease. [PDF]

Commun Med (Lond)
Kopal J, Vo A, Tao Q, Simuni T, Chahine LM, Bzdok D, Dagher A.   +6 more
europepmc   +1 more source

Clathrin-mediated endocytosis as an axis for the etiopathogenesis of Parkinson's disease. [PDF]

J Cell Sci
Kaci A, Herbst S, Manzoni C, Lewis PA.
europepmc   +1 more source

Disruption of Synaptic Vesicle Trafficking in Alzheimer's and Parkinson's Disease: Mechanisms and Therapeutic Implication. [PDF]

Int J Mol Sci
Zhu Y, Zhao L, Li Y, Tian M, Liao Y, Huang J, Guo P, Xie Y.   +7 more
europepmc   +1 more source

Transcriptional changes in the peripheral blood of at-risk individuals without clinical manifestation of Parkinson’s Disease

Whittle B, Chen C, Izuogu O, Jackson M, Santibanez-Koref M, Hudson G.   +5 more
europepmc   +1 more source

Targeting of kinases to treat neurodegenerative diseases. [PDF]

Pharmacol Rev
Shomali T, Trempe JF.
europepmc   +1 more source